Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Robert Elsby, Hayley Atkinson, Philip Butler & Robert J. Riley. (2022) Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development. Expert Opinion on Drug Metabolism & Toxicology 18:10, pages 619-655.
Read now
Read now
Mingxiang Liao, Qing Zhu, Andy Zhu, Christopher Gemski, Bingli Ma, Emily Guan, Albert P. Li, Guangqing Xiao & Cindy Q. Xia. (2019) Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans. Xenobiotica 49:7, pages 852-862.
Read now
Read now
Donna A. Volpe. (2016) Transporter assays as useful in vitro tools in drug discovery and development. Expert Opinion on Drug Discovery 11:1, pages 91-103.
Read now
Read now
Swati Jaiswal, Abhisheak Sharma, Mahendra Shukla, Kalpesh Vaghasiya, Nagarjun Rangaraj & Jawahar Lal. (2014) Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models. Drug Metabolism Reviews 46:4, pages 475-493.
Read now
Read now
Robert Elsby, Veronica Smith, Lisa Fox, David Stresser, Caroline Butters, Pradeep Sharma & Dominic D. Surry. (2011) Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions. Xenobiotica 41:9, pages 764-783.
Read now
Read now
. (2010) Invited Speakers. Drug Metabolism Reviews 42:sup1, pages 1-323.
Read now
Read now
Articles from other publishers (21)
Solène Marie, Kayla L. Frost, Raymond K. Hau, Lucy Martinez-Guerrero, Jailyn M. Izu, Cassandra M. Myers, Stephen H. Wright & Nathan J. Cherrington. (2023) Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 13:1, pages 1-28.
Crossref
Crossref
Hayley Atkinson, Robert Elsby & Philip Butler. 2022. The ADME Encyclopedia. The ADME Encyclopedia
436
447
.
Elizabeth R. Hayden, Mingqing Chen, Kyle Z. Pasquariello, Alice A. Gibson, James J. Petti, Shichen Shen, Jun Qu, Su Sien Ong, Taosheng Chen, Yan Jin, Muhammad Erfan Uddin, Kevin M. Huang, Aviv Paz, Alex Sparreboom, Shuiying Hu & Jason A. Sprowl. (2021) Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation. Clinical Cancer Research 27:15, pages 4301-4310.
Crossref
Crossref
Hayley Atkinson, Robert Elsby & Philip Butler. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
13
.
Andrea Testa, Sergio Dall’Angelo, Marco Mingarelli, Andrea Augello, Lutz Schweiger, Andrew Welch, Charles S. Elmore, Dana Dawson, Pradeep Sharma & Matteo Zanda. (2018)
Preclinical Evaluation of [
18
F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic Transporters
. Contrast Media & Molecular Imaging 2018, pages 1-10.
Crossref
Crossref
Phil Jeffrey & Scott Summerfield. 2017. Pharmacology for Chemists: Drug Discovery in Context. Pharmacology for Chemists: Drug Discovery in Context
316
342
.
Sue-Chih Lee, Vikram Arya, Xinning Yang, Donna A. Volpe & Lei Zhang. (2017) Evaluation of transporters in drug development: Current status and contemporary issues. Advanced Drug Delivery Reviews 116, pages 100-118.
Crossref
Crossref
Andrea Testa, Sergio Dall’Angelo, Marco Mingarelli, Andrea Augello, Lutz Schweiger, Andy Welch, Charles S. Elmore, Pradeep Sharma & Matteo Zanda. (2017) Design, synthesis, in vitro characterization and preliminary imaging studies on fluorinated bile acid derivatives as PET tracers to study hepatic transporters. Bioorganic & Medicinal Chemistry 25:3, pages 963-976.
Crossref
Crossref
R. Elsby, P. Martin, D. Surry, P. Sharma & K. Fenner. (2015) Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug Metabolism and Disposition 44:3, pages 398-408.
Crossref
Crossref
Marie Brännström, Pär Nordell, Britta Bonn, Andrew Davis, Anna-Pia Palmgren, Constanze Hilgendorf, Katarina Rubin & Ken Grime. (2015) Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells. Pharmaceutics 7:4, pages 554-564.
Crossref
Crossref
Andrea TestaMatteo ZandaCharles S. Elmore & Pradeep Sharma. (2015) PET Tracers To Study Clinically Relevant Hepatic Transporters. Molecular Pharmaceutics 12:7, pages 2203-2216.
Crossref
Crossref
Sreeraj Macha, R?diger Koenen, Regina Sennewald, Katja Sch?ne, Noemi Hummel, Stephan Riedmaier, Hans J. Woerle, Afshin Salsali & Uli C. Broedl. (2014) Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers. Clinical Therapeutics 36:2, pages 280-290.e1.
Crossref
Crossref
Pär Nordell, Susanne Winiwarter & Constanze Hilgendorf. (2013) Resolving the Distribution–Metabolism Interplay of Eight OATP Substrates in the Standard Clearance Assay with Suspended Human Cryopreserved Hepatocytes. Molecular Pharmaceutics 10:12, pages 4443-4451.
Crossref
Crossref
Saki Izumi, Yoshitane Nozaki, Takafumi Komori, Kazuya Maeda, Osamu Takenaka, Kazutomi Kusano, Tsutomu Yoshimura, Hiroyuki Kusuhara & Yuichi Sugiyama. (2013)
Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17
β
-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein
. Drug Metabolism and Disposition 41:10, pages 1859-1866.
Crossref
Crossref
Jose L. Ulloa, Simone Stahl, James Yates, Neil Woodhouse, J. Gerry Kenna, Huw B. Jones, John C. Waterton & Paul D. Hockings. (2013) Assessment of gadoxetate DCE‐MRI as a biomarker of hepatobiliary transporter inhibition. NMR in Biomedicine 26:10, pages 1258-1270.
Crossref
Crossref
Yurong Lai. 2013. Transporters in Drug Discovery and Development. Transporters in Drug Discovery and Development
675
718
.
Yurong Lai. 2013. Transporters in Drug Discovery and Development. Transporters in Drug Discovery and Development
353
454
.
Matthew G. Soars, Patrick Barton, Manfred Ismair, Rachael Jupp & Robert J. Riley. (2012) The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery. Drug Metabolism and Disposition 40:8, pages 1641-1648.
Crossref
Crossref
Pradeep Sharma, Caroline J. Butters, Veronica Smith, Robert Elsby & Dominic Surry. (2012) Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins. European Journal of Pharmaceutical Sciences 47:1, pages 244-255.
Crossref
Crossref
Yoshiyuki Yabe, Aleksandra Galetin & J. Brian Houston. (2011) Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs. Drug Metabolism and Disposition 39:10, pages 1808-1814.
Crossref
Crossref
Mikko Niemi, Marja K. Pasanen & Pertti J. Neuvonen. (2011) Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews 63:1, pages 157-181.
Crossref
Crossref